Reviewing VIVUS (VVUS) & Catalyst Biosciences (CBIO)
VIVUS (NASDAQ: VVUS) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
This is a breakdown of recent recommendations and price targets for VIVUS and Catalyst Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalyst Biosciences has a consensus target price of $24.50, indicating a potential upside of 353.70%. Given Catalyst Biosciences’ higher possible upside, analysts clearly believe Catalyst Biosciences is more favorable than VIVUS.
This table compares VIVUS and Catalyst Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares VIVUS and Catalyst Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|VIVUS||$133.40 million||0.77||$67.14 million||$0.31||3.13|
|Catalyst Biosciences||$561,999.00||41.41||-$19.79 million||($17.78)||-0.30|
VIVUS has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than VIVUS, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
VIVUS has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.
Institutional and Insider Ownership
35.8% of VIVUS shares are owned by institutional investors. Comparatively, 29.2% of Catalyst Biosciences shares are owned by institutional investors. 4.4% of VIVUS shares are owned by insiders. Comparatively, 5.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
VIVUS beats Catalyst Biosciences on 7 of the 12 factors compared between the two stocks.
VIVUS Company Profile
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.